Outcome of acute myocardial infarction: Low-tech value in a high-tech era

American Journal of Medicine

Volumn 110, Issue 3, 2001, Pages 221-223

  Goldman, Lee ^a  

^a UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ACETYLSALICYLIC ACID; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR;

ACUTE HEART INFARCTION; BLOOD CLOT LYSIS; CORONARY ARTERY BYPASS GRAFT; CORONARY ARTERY DILATATION; COST EFFECTIVENESS ANALYSIS; EDITORIAL; HEART MUSCLE REVASCULARIZATION; HUMAN; MEDICAL TECHNOLOGY; MORTALITY; PRIORITY JOURNAL; RISK FACTOR; RISK MANAGEMENT; TREATMENT OUTCOME;

ANGIOPLASTY, TRANSLUMINAL, PERCUTANEOUS CORONARY; CORONARY ARTERY BYPASS; HUMANS; MYOCARDIAL INFARCTION; RANDOMIZED CONTROLLED TRIALS; THROMBOLYTIC THERAPY; TREATMENT OUTCOME; UNITED STATES;

EID: 0035865857     PISSN: 00029343     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0002-9343(00)00734-8     Document Type: Editorial

References (21)

1. Trends in CHD mortality, morbidity and risk factor levels from 1960 to 1986: The Minnesota Heart Survey
2. Changes in risk factors and the decline in mortality from cardiovascular disease: The Framingham Heart Study
3. The recent decline in mortality from coronary heart disease, 1980-1990
4. Trends in treatment and outcomes for acute myocardial infarction: 1975-1995
5. Adverse outcomes of underuse of beta-blockers in elderly survivors of acute myocardial infarction
6. The health and economic benefits of increased beta-blocker utilization following myocardial infarction in the U.S
7. An international randomized trial comparing four thrombolytic strategies for acute myocardial infarction
8. Cost effectiveness of thrombolytic therapy with tissue plasminogen activator as compared with streptokinase for acute myocardial infarction
9. Long-term benefit of primary angioplasty as compared with thrombolytic therapy for acute myocardial infarction
10. Primary coronary angioplasty vs. thrombolysis for the management of acute myocardial infarction in elderly patients
11. A clinical trial comparing primary coronary angioplasty with tissue plasminogen activator for acute myocardial infarction
12. Projected cost-effectiveness of primary angioplasty for acute myocardial infarction
13. Cost and quality of life: Thrombolysis and primary angioplasty
14. Coronary angioplasty with or without stent implantation for acute myocardial infarction
15. Long-term follow-up after primary stenting versus angioplasty in acute myocardial infarction
16. The volume of primary angioplasty procedures and survival after acute myocardial infarction
17. Comparison of invasive and conservative strategies after treatment with intravenous tissue plasminogen activator in acute myocardial infarction. Results of the thrombolysis in myocardial infarction (TIMI) phase II trial
18. Effects of tissue plasminogen activator and a comparison of early invasive and conservative strategies in unstable angina and non-Q-wave myocardial infarction. Results of the TIMI IIIB trial
19. Outcomes in patients with acute non-Q-wave myocardial infarction randomly assigned to an invasive as compared with a conservative management strategy
20. Invasive compared with non-invasive treatment in unstable coronary-artery disease: FRISC II prospective randomised multicentre study. FRagmin and Fast Revascularisation during Instability in coronary artery disease investigators